Addex Therapeutics
ADXN
5 hedge funds and large institutions have $6.17M invested in Addex Therapeutics in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
35% more capital invested
Capital invested by funds: $4.59M → $6.17M (+$1.59M)
25% more funds holding
Funds holding: 4 → 5 (+1)
0.06% more ownership
Funds ownership: 0.05% → 0.11% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.64M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$32.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $3.87M | +$4.64M | +30,762 | New |
|
|
CC
2
Caxton Corporation
Princeton,
New Jersey
| $1.67M | – | – | – |
|
|
NLVP
3
New Leaf Venture Partners
New York
| $315K | – | – | – |
|
|
NMC
4
NEA Management Company
Timonium,
Maryland
| $205K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $109K | +$32.4K | +215 | +33% |
|
ADXN Hedge Fund Activity: Q4 2021 in Review
5 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q4 2021, worth a combined $6.17M — up 35% from $4.59M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ADXN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.64M.
- 5 institutional investors held Addex Therapeutics (ADXN) as of Q4 2021, up from 4 in Q3 2021.
- Funds reported $6.17M of Addex Therapeutics stock for Q4 2021, up 35% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q4 2021 and 0 closed out, a net change of +1 holder.
- The largest Addex Therapeutics buyer in Q4 2021 was Armistice Capital, an estimated $4.64M added.
Based on aggregated 13F filings for Q4 2021.